We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Adrenoleukodystrophy

This study is not yet open for participant recruitment.
Verified October 2017 by NeuroVia, Inc.
Sponsor:
ClinicalTrials.gov Identifier:
NCT03196765
First Posted: June 23, 2017
Last Update Posted: October 18, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
NeuroVia, Inc.
  Purpose
This is a phase I/II, open label dose escalation study of multiple dose levels of NV1205 with a long-term treatment phase.

Condition Intervention Phase
X-Linked Adrenoleukodystrophy Drug: Sobetirome Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Sequential Assignment
Intervention Model Description:
Sequential dose escalation
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Childhood Cerebral Adrenoleukodystrophy (CCALD)

Resource links provided by NLM:


Further study details as provided by NeuroVia, Inc.:

Primary Outcome Measures:
  • Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: 2 years ]
    Adverse events


Secondary Outcome Measures:
  • Area under the curve concentration of NV1205 in plasma [ Time Frame: 12 weeks ]
    A sparse sampling approach will be utilized to estimate a 24-hr area under the curve of NV1205 plasma concentration


Other Outcome Measures:
  • Loes score [ Time Frame: 2 years ]
    Percent change from baseline in brain lesions assessed as Loes score will be calculated


Estimated Enrollment: 25
Anticipated Study Start Date: November 1, 2017
Estimated Study Completion Date: December 1, 2020
Estimated Primary Completion Date: December 1, 2020 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Sobetirome
    Once a day oral dose of the study drug
    Other Name: NV1205
Detailed Description:

This study is to evaluate the safety, pharmacokinetics, and efficacy of NV1205 in pediatric patients diagnosed with childhood cerebral adrenoleukodystrophy (CCALD).

The study consists of:

  • Screening period: within 30 days of first dose
  • Main treatment period of 12 weeks (Part 1- from Screening to Week 12)
  • Long Term Treatment (LTT) period (Part 2- Week 13 through Week 96)

In Part 1, subjects will have an initial 4-week treatment period at the assigned dose and, if no safety concerns are noted, subjects continue for another 8 weeks of extended safety assessment.

There will be several cohorts of subjects enrolled. After each Cohort has completed the 4-week initial safety assessment, the safety data will be reviewed by an independent Data Safety Monitoring Board (DSMB) and, subject to DSMB recommendation, Cohort 2 will be enrolled and receive the next dose level. After Cohort 2 has completed 4 weeks of treatment, the DSMB will review all available safety data (Cohorts 1 and 2) and, subject to DSMB recommendation, Cohort 3 will be enrolled and receive the next dose level. Additional Cohorts may be enrolled at the recommendation of the DSMB with an incremental dose increase.

In Part 2, subjects will continue to receive treatment in the LTT period of the study.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   4 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Males ≥4 years and <18 years of age
  2. CCALD diagnosis confirmed by genetic testing
  3. Loes score of >0 and ≤15 b. Patients on VLCFA lowering agents such as Lorenzo's oil must stop the medication and have high VLCFA levels before enrollment

Exclusion Criteria:

  • Significant medical conditions such as heart, thyroid, or liver disease
  • HSCT recipients
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03196765


Contacts
Contact: Program Director 415-870-6967 patients@neurovia-inc.com

Sponsors and Collaborators
NeuroVia, Inc.
Investigators
Study Director: Masoud Mokhtarani, MD NeuroVia, Inc.
  More Information

Responsible Party: NeuroVia, Inc.
ClinicalTrials.gov Identifier: NCT03196765     History of Changes
Other Study ID Numbers: NV1205-009
First Submitted: May 5, 2017
First Posted: June 23, 2017
Last Update Posted: October 18, 2017
Last Verified: October 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by NeuroVia, Inc.:
X-ALD

Additional relevant MeSH terms:
Adrenoleukodystrophy
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Hereditary Central Nervous System Demyelinating Diseases
Leukoencephalopathies
Demyelinating Diseases
Mental Retardation, X-Linked
Intellectual Disability
Neurobehavioral Manifestations
Neurologic Manifestations
Genetic Diseases, X-Linked
Genetic Diseases, Inborn
Heredodegenerative Disorders, Nervous System
Metabolism, Inborn Errors
Peroxisomal Disorders
Metabolic Diseases
Adrenal Insufficiency
Adrenal Gland Diseases
Endocrine System Diseases